Cheche Group Providing Insurance Services For Xpeng EVs In Ten Cities

Cheche Group Inc. (NASDAQ:CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced its growing partnership with Xpeng, Inc. (NYSE:XPEV) ("Xpeng"), a leading Chinese smart

Cheche Group Inc. (NASDAQ:CCG) (“Cheche” or the “Company”), China’s leading auto insurance technology platform, today announced its growing partnership with Xpeng, Inc. (NYSE:XPEV) (“Xpeng”), a leading Chinese smart electric vehicle (“EV”) company, as Cheche continues to broaden its partner network with leaders in the EV industry.

Since Xpeng began the rollout of its latest SUV, the G6, in July, it has seen robust sales growth with August’s G6 deliveries exceeding 7,000 units (an approximately 80% month-over-month increase from July). In total, Xpeng delivered 13,690 smart EVs in August, an approximately 43% year-over-year increase from August 2022.

As Xpeng’s insurance services provider in ten cities, Cheche offers a sophisticated insurance service platform that includes SaaS systems, API management of insurers, digital operations, value-added product innovations and a nationwide service network. The EV owners can access a broad range of digital insurance options that include new policies, one-click renewals, and other value-added services. Underscoring the success of this relationship, Xpeng recognized Cheche with the Innovation Award for Better User Experience for its comprehensive, convenient, and premium services.

“The simplicity and convenience afforded to EV owners through our manufacturer collaborations enable seamless consumer access to a wide range of insurance products and services that is establishing baseline expectations within the industry,” said Lei Zhang, Founder, CEO and Chairman of Cheche. “The brand recognition and underlying growth opportunities in this channel are substantial, and we look forward to capitalizing on our ongoing relationship with Xpeng.”

The deep, strategic partnership has established a new growth model for Xpeng and integrated opportunities for Cheche’s digital insurance services. It has also demonstrated the potential for future digital insurance services and laid the groundwork for ongoing innovation and geographical expansion.

Total
0
Shares
Related Posts
Read More

Castle Biosciences Announces Publication Of Study Demonstrating DecisionDx-SCC Test Identifies High-Risk SCC Patients Benefiting Most From ART

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART

CSTL